1. Home
  2. EL vs BIIB Comparison

EL vs BIIB Comparison

Compare EL & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Estee Lauder Companies Inc. (The)

EL

Estee Lauder Companies Inc. (The)

HOLD

Current Price

$83.49

Market Cap

28.3B

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$195.34

Market Cap

27.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EL
BIIB
Founded
1946
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.3B
27.3B
IPO Year
2007
1996

Fundamental Metrics

Financial Performance
Metric
EL
BIIB
Price
$83.49
$195.34
Analyst Decision
Buy
Buy
Analyst Count
20
25
Target Price
$97.60
$206.83
AVG Volume (30 Days)
3.2M
960.2K
Earning Date
05-01-2026
04-29-2026
Dividend Yield
1.85%
N/A
EPS Growth
N/A
N/A
EPS
0.82
2.15
Revenue
$14,326,000,000.00
$9,890,600,000.00
Revenue This Year
$7.51
N/A
Revenue Next Year
$4.08
N/A
P/E Ratio
$101.01
$91.43
Revenue Growth
N/A
2.22
52 Week Low
$66.22
$121.06
52 Week High
$121.64
$205.97

Technical Indicators

Market Signals
Indicator
EL
BIIB
Relative Strength Index (RSI) 49.52 56.30
Support Level $75.26 $170.52
Resistance Level $91.60 $202.73
Average True Range (ATR) 3.08 4.76
MACD -0.38 -0.05
Stochastic Oscillator 43.96 75.96

Price Performance

Historical Comparison
EL
BIIB

About EL Estee Lauder Companies Inc. (The)

Estée Lauder is a leader in the global prestige beauty market, participating across skin care (49% of fiscal 2025 sales), makeup (29%), fragrance (17%), and hair care and others (5%). Top-selling brands include Estée Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The firm operates in more than 150 countries, generating 31% of revenue from the Americas, 37% from Europe, the Middle East and Africa (including travel retail), and 32% from Asia-Pacific. Estée Lauder sells its products through department stores, travel retail, specialty multibrand beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: